Human brain γ-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy

Journal of Neurochemistry

Volumn 67, Issue 6, 1996, Pages 2399-2404

  Petroff, Ognen A C ^a   Behar, Kevin L ^a   Mattson, Richard H ^a   Rothman, Douglas L ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

1H NMR spectroscopy; Epilepsy; Human brain; Vigabatrin; Aminobutyric acid

Indexed keywords

VIGABATRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROL SYSTEM; DRUG BRAIN LEVEL; EPILEPTOGENESIS; FEMALE; GABAERGIC TRANSMISSION; HUMAN; MALE; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; OCCIPITAL LOBE; PRIORITY JOURNAL; SEIZURE; SYNAPTOSOME;

EID: 0029824876     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1996.67062399.x     Document Type: Article

References (54)

1. 123I]iomazenil. J. Nucl. Med. 36, 167-175.
2. 31P NMR spectroscopic study of rat brain in vivo. Magn. Reson. Med. 31, 660-667.
3. 1H NMR spectra of human brain. Magn. Reson. Med. 32, 294-302.
4. Ben-Menachem E., Persson L. I., Schechter P. J., Haegele K. D., Huebert N., Hardenberg J., Dahlgren L., and Mumford J. P. (1989) The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br. J. Clin. Pharmacol. 27 (Suppl. 1), 79S-85S.
5. Ben-Menachem E., Hamberger A., and Mumford J. (1993) Effect of long-term vigabatrin therapy on GABA and other amino acid concentrations in the central nervous system - a case study. Epilepsy Res. 16, 241-243.
6. Bernasconi R., Bittiger H., Schmutz M., Martin P., and Klein M. (1984) Is the estimation of the GABA turnover rate in vivo a tool to differentiate between various types of drugs interfering with the GABA/benzodiazapine/ionophore receptor complex? Neuropharmacology 23, 815-816.
7. Böhlen P., Huot S., and Palfreyman M. G. (1979) The relationship between GABA concentrations in brain and cerebrospinal fluid. Brain Res. 167, 297-305.
8. Bolton J. B., Rimmer E., Williams J., and Richens A. (1989) The effect of vigabatrin on brain and platelet GABA-transaminase activities. Br. J. Clin. Pharmacol. 27 (Suppl. 1), 35S-42S.
9. During M. J. and Spencer D. D. (1993) Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 341, 1607-1613.
10. During M. J., Ryder K. M., and Spencer D. D. (1995) Hippocampal GABA transporter function in temporal-lobe epilepsy. Nature 376, 174-177.
11. Fischer R. S. and Kerrigan J. F. (1995) Vigabatrin: toxicity, in Antiepileptic Drugs, 4th edit. (Levy R. H., Mattson R. H., and Meldrum B. S., eds), pp. 931-939. Raven Press, New York.
12. Gardner M. J. and Altman D. G. (1989) Statistics with Confidence. British Medical Journal, London.
13. 13C]glucose. J. Neurochem. 63, 1377- 1385.
14. Halonen T., Lehtinen M., Pitkänen A., Ylinen A., and Reikkinen P. J. (1988) Inhibitory and excitatory amino acids in CSF of patients suffering with complex partial seizures during chronic treatment with gamma-vinyl GABA (vigabatrin). Epilepsy Res. 2, 246- 252.
15. Jung M. J. and Palfreyman M. G. (1995) Vigabatrin: mechanisms of action, in Antiepileptic Drugs, 4th edit. (Levy R. H., Mattson R. H., and Meldrum B. S., eds), pp. 903-913. Raven Press, New York.
16. Kälviäinen R., Halonen T., Pitkänen A., and Reikkinen P. J. (1993) Amino acid levels in the cerebrospinal fluid of newly diagnosed epileptic patients: effect of vigabatrin and carbamazepine monotherapies. J. Neurochem. 60, 1244-1250.
17. Kälviäinen R., Äikiä M., Saukkonen A. M., Mervaala E., and Reikkinen P. J. (1995) Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. Arch. Neurol. 52, 989- 996.
18. A receptor subunit mRNA concentrations following chronic lorazepam administration. Br. J. Pharmacol. 103, 1285-1287.
19. Kuzniecky R. I. and Jackson G. D. (1995) Magnetic Resonance in Epilepsy. New York, Raven Press.
20. Lambert N. and Grover L. (1995) The mechanism of biphasic GABA responses. Science 269, 928-929.
21. Löscher W. and Frey H. H. (1987) One to three day dose intervals during subchronic treatment of epileptic gerbils with gammavinyl GABA: anticonvulsant efficacy and alterations in regional brain GABA levels. Eur. J. Pharmacol. 143, 335-342.
22. Löscher W. and Schmidt D. (1994) Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. 17, 95-134.
23. Maloteaux J. M., Octave K. N., Gossuin A., Laterre C., and Trouet A. (1987) GABA induces down-regulation in the benzodiazepine- GABA receptor complex in rat cultured neurons. Eur. J. Pharmacol. 144, 173-183.
24. Manor D., Rothman D. L., Mason G. F., Hyder F., Petroff O. A. C., and Behar K. L. (1996) GABA synthesis in the rat cortex is reduced 24 hours following inhibition of GABA transaminase. (Abstr.) J. Neurochem. 66 (Suppl. 1), S81.
25. Martin D. L. (1987) Regulatory properties of brain glutamate decarboxylase. Cell. Mol. Neurobiol. 7, 237-253.
26. Martin D. L. and Rimvall K. (1993) Regulation of γ-aminobutyric acid synthesis in the brain. J. Neurochem. 60, 395-407.
27. Martin S. B. and Martin D. L. (1979) Stimulation by phosphate of the activation of glutamate apodecarboxylase by pyridoxyl-5′-phosphate and its implications for the control of GABA synthesis. J. Neurochem. 33, 1275-1283.
28. Mason G. F., Gruetter R., Rothman D. L., Behar K. L., Shulman R. G., and Novotny E. J. (1995) Simultaneous determination of the rates of the TCA cycle, glucose utilization, α-ketoglutarate/ glutamate exchange, and glutamine synthesis in human brain by NMR. J. Cereb. Blood Flow Metab. 18, 12-25.
29. Mattson R. H., Petroff O., Rothman D., and Behar K. (1994) Vigabatrin: effects on human brain GABA levels by nuclear magnetic resonance spectroscopy. Epilepsia 53 (Suppl. 5), S29-S32.
30. Mattson R. H., Petroff O. A. C., Rothman D. L., and Behar K. L. (1995) Vigabatrin: effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. Acta Neurol. Scand. Suppl. 162, 27-30.
31. Meldrum B. S. (1989) GABAergic mechanisms in the pathogenesis and treatment of epilepsy. Br. J. Clin. Pharmacol. 27 (Suppl. 1), 3S-11S.
32. 3 subunit mRNAs as well as polypeptide expression in primary cultured cerebral cortical neurons. Brain Res. Mol. Brain Res. 24, 159-165.
33. Miller L. G. (1991) Chronic benzodiazepine administration: from patient to the gene. J. Clin. Pharmacol. 31, 492-495.
34. Mumford J. P. and Cannon D. J. (1994) Vigabatrin. Epilepsia 35 (Suppl. 5), S25-S28.
35. Mumford J. P. and Dam M. (1989) Meta-analysis of European placebo controlled studies of Vigabatrin in drug resistant epilepsy. Br. J. Clin. Pharmacol. 27 (Suppl. 1), 101S-107S.
36. Penry J. K., Wilder B. J., Sachdeo R. C., et al. (1993) Multicenter dose-response study of vigabatrin in adults with focal (partial) epilepsy. (Abstr.) Epilepsia 34 (Suppl. 6), 67.
37. Petroff O. A. C., Spencer D., Alger J. R., and Prichard J. W. (1989) High-field proton magnetic resonance spectroscopy of human cerebrum obtained during surgery for epilepsy. Neurology 39, 1197-1202.
38. Petroff O. A. C., Pleban L. A., and Spencer D. D. (1995a) Symbiosis between in vivo and in vitro NMR spectroscopy: the creatine, N-acetylaspartate, glutamate, and GABA content of epileptic human brain. Magn. Reson. Imaging 13, 1197-1211.
39. 1H spectroscopic measurements of GABA, glutamate, and glutamine in human brain. Epilepsia 36, 457-464.
40. Petroff O. A. C., Rothman D. L., Behar K. L., Lamoureux D., and Mattson R. H. (1996a) The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann. Neurol. 39, 95-99.
41. Petroff O. A. C., Rothman D. L., Behar K. L., and Mattson R. H. (1995b) Human brain GABA levels rise following initiation of vigabatrin therapy, but fail to rise further with increasing dose. Neurology 46, 1459-1463.
42. Reikkinen P. J., Ylinen A., Halonen T., Sivenius J., and Pitkänen A. (1989) Cerebrospinal fluid GABA and seizure control with vigabatrin. Br. J. Clin. Pharmacol. 27 (Suppl. 1), 87S-94S.
43. 67 protein is highly sensitive to small increases in intraneuronal γ-aminobutyric acid levels. J. Neurochem. 62, 1375-1381.
44. Roberts E. (1986) Failure of GABAergic inhibition: a key to local and global seizures. Adv. Neurol. 44, 319-341.
45. 1H-double resonance difference spectroscopy of the rat brain in vivo. Proc. Natl. Acad. Sci. USA 81, 6330-6334.
46. 1H NMR measurements of GABA levels in human brain in vivo. Proc. Natl. Acad. Sci. USA 90, 5662-5666.
47. Savic I., Svanborg E., and Thorell J. O. (1996) Cortical benzodiazepine receptor changes are related to frequency of partial seizures: a positron emission tomography study. Epilepsia 37, 236-244.
48. Schechter P. J. (1989) Clinical pharmacology of vigabatrin. Br. J. Clin. Pharmacol. 27 (Suppl. 1), 19S-22S.
49. Schechter P. J. and Sjoerdsma A. (1990) Clinical relevance of measuring GABA concentrations in cerebrospinal fluid. Neurochem. Res. 15, 419-423.
50. Schechter P. J., Hanke N. F. J., Grove J., Huebert N., and Sjoerdsma A. (1984) Biochemical and clinical effects of gamma-vinyl-GABA in patients with epilepsy. Neurology 34, 182-186.
51. A receptors. Science 269, 977-981.
52. Tasker J. G. and Dudek F. E. (1991) Electrophysiology of GABA-mediated synaptic transmission and possible roles in epilepsy. Neurochem. Res. 16, 251-262.
53. A receptor/ion channel complex by intracellular GABA levels. Neurochem. Res. 16, 375-379.
54. Young R. S. K. and Petroff O. A. C. (1990) Neonatal seizure: magnetic resonance spectroscopic findings. Semin. Perinatol. 14, 238-247.